| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
01-07-2011, 11:34 AM
|
#1 | |||
|
||||
|
Senior Member
|
Biogen Idec and Neurimmune Announce Agreement on Three Neurodegenerative Disease Programs
http://www.drugsfreelist.com/medical...sease_Programs Date: 05 Jan 2011 Biogen Idec and Neurimmune Holding AG today announced that Biogen Idec has acquired a subsidiary of Neurimmune, which includes the world-wide rights to three pre-clinical immunotherapy programs. The three programs are focused on the discovery and development of novel human antibodies that address three central nervous system (CNS) targets: alpha-synuclein, tau and TDP-43. These targets are believed to be relevant for the treatment and prevention of a wide variety of neurodegenerative diseases, including Parkinson`s disease, Alzheimer`s disease and amyotrophic lateral sclerosis (ALS).
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices. ~ Jean-Martin Charcot The future is already here — it's just not very evenly distributed. William Gibson |
|||
|
 Reply With Quote
|
| "Thanks for this!" says: | Conductor71 (01-26-2011) |
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| new genetic finding of PD zeroes in on alpha synuclein | Parkinson's Disease | |||
| alpha synuclein/PD link in the news again | Parkinson's Disease | |||
| Alpha synuclein news | Parkinson's Disease | |||
| Curcumin inhibits alpha-synuclein | Parkinson's Disease | |||
| the alpha-synuclein switch / worth repeat | Parkinson's Disease | |||
immunotherapy targeting alpha synuclein, tau and TDP-43
Linear Mode
